NeoGenomics Announces the Commercial Availability of Two New Tests, Expanding Its Next-Generation Sequencing and Lung Cancer Portfolios Oct 24, 2023
NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer Jul 27, 2023
NeoGenomics' RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage Jun 15, 2023
NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer Jun 5, 2023
